Skip to main content

Table 1 The risk of 5-year mortality by 8q24.3 copy number alteration—categorized by anatomical location of each cancer—and expressed as odds ratios [OR] and 95% confidence intervals [CI]

From: Copy number of 8q24.3 drives HSF1 expression and patient outcome in cancer: an individual patient data meta-analysis

 

Total

Model 1*(n = 9568)

Model 2** (n = 7593)

Model 3*** (n = 4110)

% died

% diploid

n

Deletions (− 1 or − 2)

Gain (+ 1)

Amplification (≥ + 2)

Deletions (− 1 or − 2)

Gain (+ 1)

Amplification (≥ + 2)

Deletions (− 1 or − 2)

Gain (+ 1)

Amplification (≥ + 2)

Adrenal glands

1.8

79.8

109

 

8.60 [0.5–148.39]

       

Bladder

44.8

39.1

87

 

0.75 [0.31–1.84]

       

Blood

56.3

83.2

238

 

0.87 [0.42–1.80]

       

Brain

51.4

80.2

1,02

1.65 [0.94–2.90]

0.84 [0.56–1.24]

0.27 [0.12–0.60]

1.23 [0.79–1.92]

0.83 [0.43–1.59]

0.68 [0.37–1.25]

   

Breast

18.6

56.0

1272

1.17 [0.55–2.50]

1.05 [0.72–1.52]

1.31 [0.92–1.86]

      

Cervical

19.9

52.5

276

0.78 [0.21–2.88]

1.25 [0.68–2.32]

       

Colorectal

18.9

38.0

513

3.64 [1.31–10.17]

1.51 [0.93–2.46]

0.90 [0.25–3.25]

4.12 [1.15–14.82]

1.75 [1.32–2.31]

0.78 [0.23–2.64]

   

Esophagus

38.4

25.2

159

1.16 [0.32–4.23]

1.32 [0.60–2.88]

0.93 [0.32–2.70]

      

Eyes

26.7

24.0

75

 

9.38 [1.14–77.14]

5.67 [0.51–62.66]

      

Head and neck

39.1

27.8

468

 

1.35 [0.88–2.09]

2.23 [1.10–4.51]

 

1.40 [0.75–2.62]

2.68 [2.17–3.30]

   

Kidney

23.0

77.6

738

0.49 [0.22–1.11]

1.83 [1.17–2.87]

 

0.41 [0.21–0.82]

1.70 [0.73–3.96]

 

0.52 [0.31–0.85]

0.60 [0.23–1.62]

 

Liver

32.6

31.9

313

1.49 [0.52–4.26]

0.90 [0.52–1.57]

1.31 [0.66–2.61]

      

Lung

33.7

32.8

811

1.49 [0.76–2.90]

1.70 [1.22–2.36]

0.76 [0.37–1.56]

1.97 [1.02–3.80]

1.76 [1.24–2.51]

0.80 [0.44–1.46]

1.24 [0.34–4.51]

1.77 [1.06–2.97]

0.40 [0.10–1.65]

Mesenchyme

33.5

55.1

185

1.47 [0.60–3.56]

1.91 [0.94–3.89]

       

Mesothelium

81.3

73.3

75

 

1.08 [0.26–4.48]

       

Ovarian

47.5

16.1

503

1.81 [0.83–3.94]

1.35 [0.81–2.27]

1.01 [0.60–1.72]

1.83 [1.39–2.41]

1.53 [1.15–2.05]

1.33 [0.91–1.93]

1.52 [1.26–1.83]

7.24 [6.44–8.13]

9.73 [7.19–13.16]

Pancreas

55.8

60.4

154

 

1.87 [0.88–4.01]

1.69 [0.53–5.42]

      

Prostate

0.9

57.7

647

5.61 [0.56–56.12]

0.68 [0.07–6.56]

1.84 [0.19–17.96]

24.75 [0.8–765]

1.12 [0.76–1.64]

4.41 [3.41–5.71]

   

Skin

31.6

42.1

335

1.22 [0.48–3.11]

0.91 [0.56–1.50]

1.22 [0.48–3.11]

      

Stomach

36.3

34.8

397

0.91 [0.33–2.53]

0.60 [0.39–0.93]

0.70 [0.26–1.86]

0.93 [0.13–6.52]

0.60 [0.37–0.98]

0.56 [0.36–0.87]

   

Testicle

1.6

19.2

125

         

Thymus

5.3

89.4

113

         

Thyroid

2.4

97.4

464

         

Uterus

18.1

60.7

491

4.31 [1.70–10.88]

3.53 [2.11–5.90]

4.31 [1.62–11.48]

4.84 [2.75–8.51]

3.67 [2.03–6.66]

4.58 [1.43–14.6]

1.13 [0.16–7.78]

1.99 [1.28–3.08]

2.08 [0.06–75.09]

Total

28.3

54.1

9568

1.42 [1.16–1.73]

1.31 [1.19–1.45]

1.20 [1.02–1.40]

1.37 [0.88–2.15]

1.31 [0.78–2.20]

1.41 [0.76–2.61]

1.23 [0.69–2.16]

1.98 [1.22–3.21]

2.19 [1.13–4.26]

  1. *Model 1 is unadjusted for any confounders
  2. **Model 2 is adjusted for age, sex, calendar period, and clustering by study
  3. ***Model 3 is additionally adjusted for interaction with tumor stage and confounding by HSF1